Core Viewpoint - Gildan Activewear Inc. (GIL) is expected to report revenue growth of 7.8% year-over-year, with a consensus estimate of $885.3 million for Q4 2025, and earnings per share estimated at 94 cents, reflecting a 13.3% increase from the previous year [1]. Group 1: Financial Performance Expectations - The consensus estimate for Gildan's revenues is $885.3 million, indicating a rise of 7.8% from the year-ago figure [1]. - The consensus estimate for earnings is 94 cents per share, which indicates a 13.3% increase from the year-ago quarter's actual [1]. - Gildan has a trailing four-quarter average earnings surprise of 2.6%, with a 2% earnings surprise in the last reported quarter [2]. Group 2: Factors Influencing Q4 Results - Gildan's results are expected to benefit from its Sustainable Growth Strategy, which includes expanding capacity, driving innovation, and advancing ESG initiatives [3]. - The company has completed the acquisition of HanesBrands, contributing to increased market share through brand strength, product innovation, and enhanced customer service [4]. - The Activewear segment is gaining momentum due to market share expansion and strong demand, which is likely to positively impact the upcoming quarter's performance [4]. Group 3: Challenges and Market Conditions - The company faces challenges from a tough operating landscape, including inflationary pressures and softness in the hosiery and underwear category [5]. - Higher operating expenses are expected to have somewhat dampened profitability in the quarter under review [5]. Group 4: Valuation and Stock Performance - Gildan has a forward 12-month price-to-earnings ratio of 15.72x, which is below the industry's average of 16.41x and below its five-year high of 21.94x [7]. - Gildan shares have gained 31.2% in the past six months, significantly outperforming the industry's growth of 0.1% [7].

Key Takeaways NEM beats Q4 earnings and revenue estimates as realized gold prices surge 59.5% YoY.NEM posts $6.8B revenue, up 20.6%, while gold output hits 1.45M oz.NEM cash jumps 111% to $7.6B, debt falls 32%, and 2026 output is expected at 5.26M oz.Newmont Corporation (NEM) reported fourth-quarter 2025 earnings of $1.19 per share compared with $1.24 in the year-ago quarter.Barring one-time items, adjusted earnings were $2.52 per share, up from $1.40 reported in the prior-year quarter. It topped the Zacks ...

Key Takeaways B expands production through projects like Goldrush, Fourmile and the Lumwana Super Pit.KGC advances Round Mountain Phase X, Bald Mountain Redbird 2 and Kettle River-Curlew projects.B and KGC maintain solid liquidity and pursue development plans supported by strong gold prices.Barrick Mining Corporation (B) and Kinross Gold Corporation (KGC) are two prominent players in the gold mining space with global operations. While gold prices have fallen from their January 2026 highs, they remain favora ...

Key Takeaways FSLR's Q4 EPS is projected to rise 43% YoY, with revenues expected to increase 3.9%.FSLR may benefit from its new Louisiana plant and up to $391M in 45X tax credit proceeds.FSLR is expected to face tariff-driven cost pressures and softer Malaysia, Vietnam output in Q4.First Solar (FSLR) is scheduled to release fourth-quarter 2025 results on Feb. 24, after market close. The company delivered a negative earnings surprise of 1.9% in the last reported quarter. Let’s discuss the factors that are li ...

Key Takeaways ALLT is expected to post Q4 revenues of $27.93M, up 12.2% Y/Y, with EPS of 7 cents.Allot's SECaaS ARR jumped about 60% Y/Y in Q3, lifting recurring revenues to 63% of total sales.ALLT trades at 4.21X forward sales, below sector and major cybersecurity peers.Allot Inc. (ALLT) is scheduled to report its fourth-quarter 2025 results on Feb. 25.The Zacks Consensus Estimate for Allot’s fourth-quarter 2025 revenues is pegged at $27.93 million, which implies growth of 12.2% from the year-ago reported ...

Key Takeaways OLED reported Q4 EPS of $1.39, up from 96 cents, as revenues rose to $173M and met estimates.Material sales and royalties drove growth, with green emitter sales climbing to $74M in the quarter.OLED expects revenues of $650M-$700M and gross margin of 74%-76% in 2026.Universal Display Corporation (OLED) reported relatively healthy fourth-quarter 2025 results, with adjusted earnings beating Zacks Consensus Estimate while the top line matched the same. The company reported a top-line expansion yea ...

Key Takeaways DTI is using its OneDTI program to unify operations and protect margins ahead of a 2025 downturn.Drilling Tools International grew Eastern Hemisphere revenues 41% year over year in Q3 2025.DTI's Compass platform and Houston facility move are boosting efficiency and lowering costs.In the cyclical oilfield services sector, execution and integration often determine which companies outperform when activity slows. Drilling Tools International (DTI) is addressing the near-term downturn by prioritizi ...

Key Takeaways Workday will report Q4 fiscal 2026 results on Feb 24 after posting steady earnings surprises.WDAY saw demand for HCM and finance tools, expanded Workday GO and launched EU Sovereign Cloud.Workday's Earnings ESP is -3.86%, making an earnings beat less certain this quarter.Workday, Inc. (WDAY) is set to release fourth-quarter fiscal 2026 results on Feb. 24, after the closing bell. In the trailing four quarters, the company delivered an earnings surprise of 9.11%, while in the last reported quart ...

Key Takeaways Comfort Systems crushed the fourth-quarter results with the EPS surging 129% and revenues growing 42% YoY.Comfort Systems' backlog nearly doubled as it rides on the robust data center demand trends.FIX's margins expanded year over year, with lifted cash flow and shareholders' returns spreading optimism.Comfort Systems USA, Inc. (FIX) delivered stellar fourth-quarter 2025 results, with adjusted earnings and revenues surpassing the Zacks Consensus Estimate and increasing year over year.FIX stock ...

Core Insights - AbbVie reported strong fourth-quarter and full-year 2025 results, surpassing expectations, primarily driven by its newer immunology drugs, Rinvoq and Skyrizi, which offset the decline of the legacy drug Humira [1] Financial Performance - Skyrizi and Rinvoq generated combined revenues of approximately $26 billion, reflecting over 40% year-over-year growth. Skyrizi sales increased by 50% year-over-year to $17.56 billion, while Rinvoq sales rose by 39% to $8.30 billion [2] - AbbVie anticipates overall sales to grow at a high single-digit revenue CAGR through 2029, with combined sales of Skyrizi and Rinvoq expected to exceed $31 billion in 2026, surpassing the long-term guidance of $31 billion for 2027 [4] Market Dynamics - The immunology market is experiencing strong growth, with significant market share gains for Skyrizi in psoriasis and Rinvoq in rheumatoid arthritis. New indications for both drugs, including recent approvals and potential future approvals, are expected to drive further growth [3][5] - AbbVie expects Rinvoq to secure approvals for vitiligo and alopecia areata in 2026, with additional phase III data anticipated for hidradenitis suppurativa and systemic lupus erythematosus [5] Competitive Landscape - AbbVie faces competition from Johnson & Johnson, which markets Stelara and Tremfya, and Eli Lilly, which recently received FDA approval for Omvoh in ulcerative colitis [7][8] Valuation and Estimates - AbbVie shares are currently trading at a P/E ratio of 15.14, below the industry average of 18.74, but above its five-year mean of 13.68 [12] - Estimate revisions for 2026 EPS have trended higher, while those for 2027 have decreased over the past 30 days [14]